Fremanezumab and Non-High-Dose Galcanezumab for Comorbid Cluster Headache in Patients with Migraine: Three Cases
A new treatment option for cluster headache (CH) prevention is needed. Monoclonal antibodies (mABs) against calcitonin gene-related peptide (CGRP) ligands are used as a preventative treatment for migraine. Considering the CGRP's role in the CH attack's ignition and upkeep, fremanezumab and...
Saved in:
Main Authors: | Kenta Kashiwagi (Author), Masahito Katsuki (Author), Shin Kawamura (Author), Senju Tachikawa (Author), Atsuko Ono (Author), Akihito Koh (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2023-02-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Efficacy of galcanezumab in patients with episodic cluster headaches and a history of preventive treatment failure
by: Brian Plato, et al.
Published: (2021) -
Efficacy and safety of galcanezumab for prevention of migraine headache in Japanese patients with episodic migraine: A phase 2 randomized controlled clinical trial
by: Fumihiko Sakai, et al.
Published: (2020) -
Erratum to "Efficacy of galcanezumab in patients with episodic cluster headaches and a history of preventive treatment failure"
Published: (2021) -
The Role of Galcanezumab in Migraine Prevention: Existing Data and Future Directions
by: Panagiotis Gklinos, et al.
Published: (2021) -
ID275 Anticorpos monoclonais (erenumabe, galcanezumabe, eptinezumabe e fremanezumabe) no tratamento do transtorno de enxaqueca: uma revisão sistemática e metanálise
by: Bruna Carolina de Araújo, et al.
Published: (2024)